Novartis' KAE609 effective in uncomplicated malaria patients

31 July 2014

Swiss drug major Novartis (NOVN: VX) says that results published in the New England Journal of Medicine show that antimalarial drug candidate KAE609 (cipargamin) cleared the parasite rapidly in plasmodium falciparum (P. falxiparum) and Plasmodium vivax (P. vivax) uncomplicated malaria patients.

KAE609 is one of two candidates Novartis is currently developing, and it, along with KAF 156, are new classes of anti-malarial compounds that work differently to current therapies.

Joseph Jimenez, chief executive of Novartis, said: "Novartis is in the fight against malaria for the long term and we are committed to the continued research and development of new therapies to eventually eliminate the disease. With two compounds and a new drug target currently under investigation, Novartis has one of the strongest malaria pipelines in the industry."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK